ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction. It also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic heart failure. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ABIO
CUSIPN/A
Phone720-940-2200
Debt
Debt-to-Equity RatioN/A
Current Ratio9.44
Quick Ratio9.44
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.87 per share
Price / Book0.60
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-18,490,000.00
Net MarginsN/A
Return on Equity-120.72%
Return on Assets-103.45%
Miscellaneous
Employees20
Outstanding Shares13,920,000
Market Cap$7.24 million
Arca Biopharma (NASDAQ:ABIO) Frequently Asked Questions
What is Arca Biopharma's stock symbol?
Arca Biopharma trades on the NASDAQ under the ticker symbol "ABIO."
How were Arca Biopharma's earnings last quarter?
Arca Biopharma Inc (NASDAQ:ABIO) announced its earnings results on Thursday, August, 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. View Arca Biopharma's Earnings History.
When is Arca Biopharma's next earnings date?
What price target have analysts set for ABIO?
1 analysts have issued twelve-month price objectives for Arca Biopharma's shares. Their forecasts range from $2.00 to $2.00. On average, they expect Arca Biopharma's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 284.6% from the stock's current price. View Analyst Price Targets for Arca Biopharma.
What is the consensus analysts' recommendation for Arca Biopharma?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arca Biopharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arca Biopharma.
Who are some of Arca Biopharma's key competitors?
Who are Arca Biopharma's key executives?
Arca Biopharma's management team includes the folowing people:
- Dr. Michael R. Bristow, Co-Founder, Pres, CEO & Director (Age 73)
- Mr. Thomas A. Keuer, Chief Operating Officer (Age 59)
- Mr. Christopher D. Ozeroff, Sr. VP, Gen. Counsel & Sec. (Age 59)
- Mr. Brian L. Selby, Chief Accounting Officer & VP of Fin. (Age 56)
- Monique Plamondon, VP of Regulatory Affairs & QA
Has Arca Biopharma been receiving favorable news coverage?
Headlines about ABIO stock have been trending somewhat positive on Thursday, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Arca Biopharma earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Arca Biopharma.
Who are Arca Biopharma's major shareholders?
Arca Biopharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (3.01%). Company insiders that own Arca Biopharma stock include Brian L Selby, Christopher David Ozeroff, Daniel J Mitchell, Michael R Bristow, Ravi Viswanathan, Robert E Conway and Thomas A Keuer. View Institutional Ownership Trends for Arca Biopharma.
Which institutional investors are selling Arca Biopharma stock?
ABIO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have sold Arca Biopharma company stock in the last year include Brian L Selby, Ravi Viswanathan and Thomas A Keuer. View Insider Buying and Selling for Arca Biopharma.
How do I buy shares of Arca Biopharma?
Shares of ABIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arca Biopharma's stock price today?
One share of ABIO stock can currently be purchased for approximately $0.52.
How big of a company is Arca Biopharma?
Arca Biopharma has a market capitalization of $7.24 million. Arca Biopharma employs 20 workers across the globe.
How can I contact Arca Biopharma?
Arca Biopharma's mailing address is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. The biopharmaceutical company can be reached via phone at 720-940-2200 or via email at [email protected]
MarketBeat Community Rating for Arca Biopharma (NASDAQ ABIO)
MarketBeat's community ratings are surveys of what our community members think about Arca Biopharma and other stocks. Vote "Outperform" if you believe ABIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
